Novartis Eyes Liver Safety Biomarker As Potential Path To Prexige Approval
Executive Summary
Novartis has identified a genetic sequence that may be a risk factor for serious liver injury in patients receiving Prexige (lumiracoxib), a finding that may signal a development path forward for the COX-2 inhibitor
You may also be interested in...
Will COX-2 + Biomarker = Success? Novartis Tests the Frontiers of Companion Diagnostics
A new genetic blood test that identifies patients at risk of liver toxicities may give Joicela (formerly Prexige) new life.
Will COX-2 + Biomarker = Success? Novartis Tests the Frontiers of Companion Diagnostics
A new genetic blood test that identifies patients at risk of liver toxicities may give Joicela (formerly Prexige) new life.
Serious Adverse Events Consortium Expects Data On Genetic Variants Shortly
Initial data generated by the Serious Adverse Events Consortium with regard to DNA variants associated with drug-related serious skin rash will be available at the end of 2008 or in January 2009, SAEC executive director Arthur Holden predicts